ArticleFrontiers in pediatrics2025
Markers of enterocyte damage in celiac disease in children: is there an association with the clinical manifestations of the disease?
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actuality: The state of the intestinal barrier has crucial importance in the pathogenesis of celiac disease (CD). Fecal zonulin (FZ) and intestinal fatty acid binding protein (i-FABP) are important components in maintaining physiological processes in the intestine and potential biomarkers of enterocyte damage. Aim of study: To evaluate FZ and i-FABP levels as markers of small intestine injury in children with CD, depending on the clinical forms and histomorphological changes in the small intestinal mucosa. Materials and methods: In 2021-2023 yy, a single-center observational study was conducted among children with newly diagnosed CD.The level of FZ in stool and I-FABP in serum were determined using the Immundiagnostik ELISA kits (Germany). Results: Study included 75 patients,control group was 37 healthy children. The intestinal form of the CD was established in 51 (68.0%) patients,the remaining 24 (32.0%) children have CD with extraintestinal manifestations. Among children with classical CD, the mean values of FZ were 157.9 ± 29.8 ng/ml ( Conclusions: Our study demonstrated a relationship between the clinical manifestations of CD and the levels of FZ and i-FABP. The increase in the values also can serve as marker of increased permeability and damage of the intestinal barrier, which will open up new possibilities for understanding the processes of restoration of the small intestinal mucosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.